• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Globus Medical (GMED) Unveils New Spine Platforms Following A Narrative Of Undervaluation

    Simply Wall St·10/17/2026 19:31:43
    语音播报

    Globus Medical (GMED) just used the North American Spine Society meeting to put two new spine platforms in front of surgeons: SCRIPT for patient specific implants and the XLIF Prone Procedural Solution.

    Globus Medical shares closed at US$76.71 on 16 October, with the 7 day share price return of 2.76% and 30 day share price return of 1.93% hinting at modest positive momentum. The year to date share price return is down 12.13%, despite a 1 year total shareholder return of 28.75% and 3 year total shareholder return of 49.50%, suggesting long term holders have still seen meaningful gains even as near term sentiment has cooled.

    Spot emerging peers riding similar themes in spine robotics and patient specific care by running Globus Medical alongside our curated 33 healthcare AI stocks.

    Globus Medical now has fresh products on show and a share price that is still below recent highs. The question is whether that tilts the balance toward buying today or being patient for a cheaper entry before SCRIPT scales up.

    Most Popular Narrative: 24% Undervalued

    Globus Medical closed at $76.71 while the most followed narrative pegs fair value at about $100.92, so the current price bakes in a sizeable discount before even accounting for SCRIPT or XLIF Prone gaining traction.

    Expansion of the musculoskeletal and digital platform through trauma growth, integration of Nevro and the Higgs Boson Health acquisition for AI driven surgical intelligence provides additional ways to capture procedure volume, which can scale both revenue and adjusted EBITDA over time.

    See why 21 investors see Globus Medical as 24% undervalued.

    Result: Fair Value of $100.92 (UNDERVALUED)

    Still, the narrative can crack if Enabling Technologies and Nevro continue to weigh on segment trends, or if hospital pricing pressure restrains spine and neuromodulation volumes.

    Find out about the key risks to this Globus Medical narrative.

    Next Steps

    Views on Globus Medical in this article lean constructive, so do not just accept the headline mood. Pull up the numbers, pressure test the assumptions, and see how they square with 5 key rewards.

    Looking for more Globus Medical style investment ideas?

    Do not stop with Globus Medical. If you want a broader watchlist that could surface the next stock on your radar, put the Simply Wall St Screener to work.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.